Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Altamira Therapeutics Ltd. CYTO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • BM • USD

SharesGrow Score
33/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Altamira Therapeutics Ltd. (CYTO) is a Biotechnology company in the Healthcare sector, currently trading at $0.30. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $7M (loss), growing at -30.3%/yr. Net profit margin is 0% (thin). Gross margin is -372.4% (-472.4 pp trend).

Balance sheet: total debt is $361,053 against $7M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 1.32 (adequate). Debt-to-assets is 4.2%. Total assets: $9M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 0/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

CYTO SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CYTO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
CYTO: +71.7%/yr revenue is, -30.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet CYTO: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 1.32 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.3-0.4158
Volume724.3K
Avg Volume (30D)244.03K
Market Cap$1.13M
Beta (1Y)2.44
Share Statistics
EPS (TTM)-14.81
Shares Outstanding$491K
IPO Date2014-08-06
Employees10
CEOThomas Meyer
Financial Highlights & Ratios
EBITDA$-1.35M
Net Income$-7.27M
Operating Income$-5.92M
Total Cash$998.62K
Total Debt$361.05K
Net Debt$-637.57K
Total Assets$8.65M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryBM
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINBMG0360L1349

Price Chart

Track all markets on TradingView
CYTO
Altamira Therapeutics Ltd. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.30 52WK RANGE 0.42

People Also View

VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 PALI
PALI
Palisade Bio, Inc.
$2.06
+3.52%
 PYXS
PYXS
Pyxis Oncology, Inc.
$1.70
-0.58%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message